<!doctype html>
<html>
<head>
<meta charset="UTF-8">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="viewport" content="width=device-width initial-scale=1, user-scalable=no">
<meta name="apple-mobile-web-app-title" content="AstraZeneca | LYNPARZA">
<title>AstraZeneca | LYNPARZA</title>
<link rel="stylesheet" type="text/css" href="css/animate.min.css" />
<link rel="stylesheet" type="text/css" href="css/style.css" />
<script src="http://ajax.googleapis.com/ajax/libs/jquery/1.9.1/jquery.min.js"></script>
<style type="text/css">
.bodyContent {margin-top:111px; margin-left:68px; width:888px; height:555px; background-color: #003665; }
.bodyContent > li {font-family: "lexiRegular"; font-size: 24px; line-height: 30px; color: white; margin-bottom: 16px; padding-left: 38px;
padding-right: 29px; }
ul {list-style: none;}
.bodyContent > li:first-child {padding-top:69px;}
.bodyContent > li:nth-child(3) { margin-bottom: 26px; }

.bodyContent > ul:nth-child(4) {padding-left: 38px; color: white;}
.bodyContent > ul:nth-child(4) { font-size:14px; font-family: "HelveticaNeueLTStd";  line-height: 16px;}
.bodyContent > ul:nth-child(4) > li:nth-child(4), .bodyContent > ul:nth-child(4) > li:nth-child(5) {margin-left: 15px;}

</style> 

</head>
<body>
	<section id="container">

    	<article class="content">

            <span></span>
        </article>
    		         <!--popups -->
        <div class="popup">
            <span class="close"></span>
            <ul class="bodyContent">
                <li>A systematic review and network meta-analysis funded by the Canadian government* set out to answer the question: “What is the comparative effectiveness and safety of long-acting inhaled agents (ICS, LABA, LAMA) alone or in any combination for patients with COPD?”#</li>
                <li>More than 200 RCTs in 134,692 patients were reviewed in one of the most comprehensive systematic reviews published to date.</li>
                <li>The results from 20 RCTs of at least 12 weeks duration in 26,141 patients showed that Spiriva®/Symbicort® (triple therapy) was associated with the 
                    highest probability of reducing the risk of moderate-to-severe exacerbations 
                    for patients who experienced an exacerbation in the last year.1 # </li>
                <ul>
                    <li>*Ontario Ministry of Health and Long-Term Care Health System Research Fund</li>
                    <li>RCT = randomised controlled trial.</li>
                    <li># The authors highlighted several limitations of this analysis:</li>
                    <li>– since the original literature search in Dec. 2013, 21 new trials were published; particularly evident for LAMA/LABA combinations.</li>
                    <li>– many of the included RCTs were at high risk of bias, in terms of Cochrane risk-of-bias-criteria.</li>
                </ul>
            </ul>
        </div>
    </section>

<script type="text/javascript" src="js/jquery-1.11.0.min.js"></script>
<script type="text/javascript" src="js/touchy.js"></script>
<script type="text/javascript" src="js/script.js"></script>
<script type="text/javascript">
	$( function(){

	});



</script>
</body>
</html>
